Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1997 Oct;71(10):7623–7628. doi: 10.1128/jvi.71.10.7623-7628.1997

Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver.

J T Bruder 1, T Jie 1, D L McVey 1, I Kovesdi 1
PMCID: PMC192111  PMID: 9311844

Abstract

Activation of the cellular immune system and subsequent lysis of vector-transduced cells by adenovirus- or transgene-specific cytotoxic T lymphocytes have been shown to limit transgene expression in animal models. The adenovirus gp19K gene product associates with major histocompatibility complex class I proteins and prevents their maturation by sequestering them in the endoplasmic reticulum. gp19K has been shown to block the ability of adenovirus-specific cytotoxic T lymphocytes to recognize virus-infected cells in vitro. To determine if gp19K expression in an adenovirus vector would increase transgene persistence, a vector that replaces the E1 region of adenovirus with an expression cassette encoding both gp19K and beta-glucuronidase was constructed. This vector produced high levels of functional gp19K in infected cells. RNase protection analysis revealed efficient expression of the gp19K gene in the mouse lung. Enhanced persistence and increased beta-glucuronidase activity were observed in the lung and liver following delivery of the gp19K-expressing adenovirus vector in B10.HTG mice but not in BALB/c mice. Since gp19K binds to both class I alleles on B10.HTG mice but only one allele on BALB/c mice, these results suggest that the major histocompatibility complex class I haplotype of mice is important in determining the effectiveness of gp19K in vivo. Since gp19K has previously been shown to interact with every human major histocompatibility complex class I allele tested, the inclusion of gp19K in gene therapy vectors may increase vector persistence in human gene therapy trials.

Full Text

The Full Text of this article is available as a PDF (668.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adesanya M. R., Redman R. S., Baum B. J., O'Connell B. C. Immediate inflammatory responses to adenovirus-mediated gene transfer in rat salivary glands. Hum Gene Ther. 1996 Jun 10;7(9):1085–1093. doi: 10.1089/hum.1996.7.9-1085. [DOI] [PubMed] [Google Scholar]
  2. Ahn K., Meyer T. H., Uebel S., Sempé P., Djaballah H., Yang Y., Peterson P. A., Früh K., Tampé R. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J. 1996 Jul 1;15(13):3247–3255. [PMC free article] [PubMed] [Google Scholar]
  3. Amalfitano A., Begy C. R., Chamberlain J. S. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3352–3356. doi: 10.1073/pnas.93.8.3352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Andersson M., Päbo S., Nilsson T., Peterson P. A. Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell. 1985 Nov;43(1):215–222. doi: 10.1016/0092-8674(85)90026-1. [DOI] [PubMed] [Google Scholar]
  5. Beier D. C., Cox J. H., Vining D. R., Cresswell P., Engelhard V. H. Association of human class I MHC alleles with the adenovirus E3/19K protein. J Immunol. 1994 Apr 15;152(8):3862–3872. [PubMed] [Google Scholar]
  6. Brough D. E., Lizonova A., Hsu C., Kulesa V. A., Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol. 1996 Sep;70(9):6497–6501. doi: 10.1128/jvi.70.9.6497-6501.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Burgert H. G., Kvist S. The E3/19K protein of adenovirus type 2 binds to the domains of histocompatibility antigens required for CTL recognition. EMBO J. 1987 Jul;6(7):2019–2026. doi: 10.1002/j.1460-2075.1987.tb02466.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Burgert H. G., Maryanski J. L., Kvist S. "E3/19K" protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens. Proc Natl Acad Sci U S A. 1987 Mar;84(5):1356–1360. doi: 10.1073/pnas.84.5.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chinnadurai G., Chinnadurai S., Brusca J. Physical mapping of a large-plaque mutation of adenovirus type 2. J Virol. 1979 Nov;32(2):623–628. doi: 10.1128/jvi.32.2.623-628.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cox J. H., Bennink J. R., Yewdell J. W. Retention of adenovirus E19 glycoprotein in the endoplasmic reticulum is essential to its ability to block antigen presentation. J Exp Med. 1991 Dec 1;174(6):1629–1637. doi: 10.1084/jem.174.6.1629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cox J. H., Buller R. M., Bennink J. R., Yewdell J. W., Karupiah G. Expression of adenovirus E3/19K protein does not alter mouse MHC class I-restricted responses to vaccinia virus. Virology. 1994 Nov 1;204(2):558–562. doi: 10.1006/viro.1994.1569. [DOI] [PubMed] [Google Scholar]
  12. Cox J. H., Yewdell J. W., Eisenlohr L. C., Johnson P. R., Bennink J. R. Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum. Science. 1990 Feb 9;247(4943):715–718. doi: 10.1126/science.2137259. [DOI] [PubMed] [Google Scholar]
  13. DeMatteo R. P., Markmann J. F., Kozarsky K. F., Barker C. F., Raper S. E. Prolongation of adenoviral transgene expression in mouse liver by T lymphocyte subset depletion. Gene Ther. 1996 Jan;3(1):4–12. [PubMed] [Google Scholar]
  14. Engelhardt J. F., Ye X., Doranz B., Wilson J. M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6196–6200. doi: 10.1073/pnas.91.13.6196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fisher K. J., Choi H., Burda J., Chen S. J., Wilson J. M. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology. 1996 Mar 1;217(1):11–22. doi: 10.1006/viro.1996.0088. [DOI] [PubMed] [Google Scholar]
  16. Gao G. P., Yang Y., Wilson J. M. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol. 1996 Dec;70(12):8934–8943. doi: 10.1128/jvi.70.12.8934-8943.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ginsberg H. S., Horswood R. L., Chanock R. M., Prince G. A. Role of early genes in pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A. 1990 Aug;87(16):6191–6195. doi: 10.1073/pnas.87.16.6191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ginsberg H. S., Lundholm-Beauchamp U., Horswood R. L., Pernis B., Wold W. S., Chanock R. M., Prince G. A. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci U S A. 1989 May;86(10):3823–3827. doi: 10.1073/pnas.86.10.3823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ginsberg H. S., Moldawer L. L., Sehgal P. B., Redington M., Kilian P. L., Chanock R. M., Prince G. A. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1651–1655. doi: 10.1073/pnas.88.5.1651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Graham F. L., Smiley J., Russell W. C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977 Jul;36(1):59–74. doi: 10.1099/0022-1317-36-1-59. [DOI] [PubMed] [Google Scholar]
  21. Grunhaus A., Cho S., Horwitz M. S. Association of vaccinia virus-expressed adenovirus E3-19K glycoprotein with class I MHC and its effects on virulence in a murine pneumonia model. Virology. 1994 May 1;200(2):535–546. doi: 10.1006/viro.1994.1216. [DOI] [PubMed] [Google Scholar]
  22. Guérette B., Vilquin J. T., Gingras M., Gravel C., Wood K. J., Tremblay J. P. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Hum Gene Ther. 1996 Aug 1;7(12):1455–1463. doi: 10.1089/hum.1996.7.12-1455. [DOI] [PubMed] [Google Scholar]
  23. Haecker S. E., Stedman H. H., Balice-Gordon R. J., Smith D. B., Greelish J. P., Mitchell M. A., Wells A., Sweeney H. L., Wilson J. M. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther. 1996 Oct 1;7(15):1907–1914. doi: 10.1089/hum.1996.7.15-1907. [DOI] [PubMed] [Google Scholar]
  24. Jefferies W. A., Burgert H. G. E3/19K from adenovirus 2 is an immunosubversive protein that binds to a structural motif regulating the intracellular transport of major histocompatibility complex class I proteins. J Exp Med. 1990 Dec 1;172(6):1653–1664. doi: 10.1084/jem.172.6.1653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kaplan J. M., Armentano D., Sparer T. E., Wynn S. G., Peterson P. A., Wadsworth S. C., Couture K. K., Pennington S. E., St George J. A., Gooding L. R. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum Gene Ther. 1997 Jan 1;8(1):45–56. doi: 10.1089/hum.1997.8.1-45. [DOI] [PubMed] [Google Scholar]
  26. Kay M. A., Holterman A. X., Meuse L., Gown A., Ochs H. D., Linsley P. S., Wilson C. B. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet. 1995 Oct;11(2):191–197. doi: 10.1038/ng1095-191. [DOI] [PubMed] [Google Scholar]
  27. Kochanek S., Clemens P. R., Mitani K., Chen H. H., Chan S., Caskey C. T. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5731–5736. doi: 10.1073/pnas.93.12.5731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kolls J. K., Lei D., Odom G., Nelson S., Summer W. R., Gerber M. A., Shellito J. E. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum Gene Ther. 1996 Mar 1;7(4):489–497. doi: 10.1089/hum.1996.7.4-489. [DOI] [PubMed] [Google Scholar]
  29. Krougliak V., Graham F. L. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther. 1995 Dec;6(12):1575–1586. doi: 10.1089/hum.1995.6.12-1575. [DOI] [PubMed] [Google Scholar]
  30. Kumar-Singh R., Chamberlain J. S. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Genet. 1996 Jul;5(7):913–921. doi: 10.1093/hmg/5.7.913. [DOI] [PubMed] [Google Scholar]
  31. Kvist S., Ostberg L., Persson H., Philipson L., Peterson P. A. Molecular association between transplantation antigens and cell surface antigen in adenovirus-transformed cell line. Proc Natl Acad Sci U S A. 1978 Nov;75(11):5674–5678. doi: 10.1073/pnas.75.11.5674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Lee M. G., Abina M. A., Haddada H., Perricaudet M. The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther. 1995 Jun;2(4):256–262. [PubMed] [Google Scholar]
  33. Lieber A., He C. Y., Kirillova I., Kay M. A. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol. 1996 Dec;70(12):8944–8960. doi: 10.1128/jvi.70.12.8944-8960.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Poller W., Schneider-Rasp S., Liebert U., Merklein F., Thalheimer P., Haack A., Schwaab R., Schmitt C., Brackmann H. H. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Ther. 1996 Jun;3(6):521–530. [PubMed] [Google Scholar]
  35. Päbo S., Bhat B. M., Wold W. S., Peterson P. A. A short sequence in the COOH-terminus makes an adenovirus membrane glycoprotein a resident of the endoplasmic reticulum. Cell. 1987 Jul 17;50(2):311–317. doi: 10.1016/0092-8674(87)90226-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Rawle F. C., Tollefson A. E., Wold W. S., Gooding L. R. Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp19K but not E3 14.7K. J Immunol. 1989 Sep 15;143(6):2031–2037. [PubMed] [Google Scholar]
  37. Routes J. M., Metz B. A., Cook J. L. Endogenous expression of E1A in human cells enhances the effect of adenovirus E3 on class I major histocompatibility complex antigen expression. J Virol. 1993 Jun;67(6):3176–3181. doi: 10.1128/jvi.67.6.3176-3181.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Severinsson L., Martens I., Peterson P. A. Differential association between two human MHC class I antigens and an adenoviral glycoprotein. J Immunol. 1986 Aug 1;137(3):1003–1009. [PubMed] [Google Scholar]
  39. Sparer T. E., Tripp R. A., Dillehay D. L., Hermiston T. W., Wold W. S., Gooding L. R. The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. J Virol. 1996 Apr;70(4):2431–2439. doi: 10.1128/jvi.70.4.2431-2439.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Tanaka Y., Tevethia S. S. Differential effect of adenovirus 2 E3/19K glycoprotein on the expression of H-2Kb and H-2Db class I antigens and H-2Kb- and H-2Db-restricted SV40-specific CTL-mediated lysis. Virology. 1988 Aug;165(2):357–366. doi: 10.1016/0042-6822(88)90580-6. [DOI] [PubMed] [Google Scholar]
  41. Tomazin R., Hill A. B., Jugovic P., York I., van Endert P., Ploegh H. L., Andrews D. W., Johnson D. C. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J. 1996 Jul 1;15(13):3256–3266. [PMC free article] [PubMed] [Google Scholar]
  42. Vilquin J. T., Guérette B., Kinoshita I., Roy B., Goulet M., Gravel C., Roy R., Tremblay J. P. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther. 1995 Nov;6(11):1391–1401. doi: 10.1089/hum.1995.6.11-1391. [DOI] [PubMed] [Google Scholar]
  43. Wang Q., Finer M. H. Second-generation adenovirus vectors. Nat Med. 1996 Jun;2(6):714–716. doi: 10.1038/nm0696-714. [DOI] [PubMed] [Google Scholar]
  44. Yang Y., Ertl H. C., Wilson J. M. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity. 1994 Aug;1(5):433–442. doi: 10.1016/1074-7613(94)90074-4. [DOI] [PubMed] [Google Scholar]
  45. Yang Y., Greenough K., Wilson J. M. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 1996 May;3(5):412–420. [PubMed] [Google Scholar]
  46. Yang Y., Li Q., Ertl H. C., Wilson J. M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1995 Apr;69(4):2004–2015. doi: 10.1128/jvi.69.4.2004-2015.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Yang Y., Nunes F. A., Berencsi K., Furth E. E., Gönczöl E., Wilson J. M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4407–4411. doi: 10.1073/pnas.91.10.4407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Yang Y., Su Q., Grewal I. S., Schilz R., Flavell R. A., Wilson J. M. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol. 1996 Sep;70(9):6370–6377. doi: 10.1128/jvi.70.9.6370-6377.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Yang Y., Su Q., Wilson J. M. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol. 1996 Oct;70(10):7209–7212. doi: 10.1128/jvi.70.10.7209-7212.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Yang Y., Trinchieri G., Wilson J. M. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med. 1995 Sep;1(9):890–893. doi: 10.1038/nm0995-890. [DOI] [PubMed] [Google Scholar]
  51. Yeh P., Dedieu J. F., Orsini C., Vigne E., Denefle P., Perricaudet M. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol. 1996 Jan;70(1):559–565. doi: 10.1128/jvi.70.1.559-565.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES